EGFR and adenocarcinoma: Although immunotherapy, such as immune checkpoint inhibitors (ICIs), has recently been highlighted,4 epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are recommended as a first‐line therapy for patients with advanced adenocarcinoma with EGFR mutation.5, 6